Formulation and Structural Optimisation of PVA-Fibre Biopolymer Composites for 3D Printing in Drug Delivery Applications.

Additive manufacturing using fused deposition modelling (FDM) is increasingly explored for personalised drug delivery, but the lack of suitable biodegradable and printable filaments limits its pharmaceutical application. In this study, we investigated the influence of formulation and structural design on the performance of polyvinyl alcohol (PVA)-based filaments doped with theophylline anhydrous for 3D printing. To address the intrinsic brittleness and poor printability of PVA, cassava pulp-derived fibres-a sustainable and underutilised agricultural by-product-were incorporated together with polyethylene glycol (PEG 400), Eudragit^® NE 30 D, and calcium stearate. The addition of fibres modified the mechanical properties of PVA filaments through hydrogen bonding, improving flexibility but increasing surface roughness. This drawback was mitigated by Eudragit^® NE 30 D, which enhanced surface smoothness and drug distribution uniformity. The optimised composite formulation (P₁₀F₅E₅T₅) was successfully extruded and used to fabricate 3D-printed constructs. Release studies demonstrated that drug release could be modulated by pore geometry and construct thickness: wider pores enabled rapid Fickian diffusion, while narrower pores and thicker constructs shifted release kinetics toward anomalous transport governed by polymer swelling. These findings demonstrate, for the first time, the potential of cassava fibre as a functional additive in pharmaceutical FDM and provide a rational formulation-structure-performance framework for developing sustainable, geometry-tuneable drug delivery systems.